Control of filarial infections: Not the beginning of the end, but more research is needed

Current Opinion in Infectious Diseases

Volumn 16, Issue 5, 2003, Pages 403-410

  Hoerauf, Achim ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Chemotherapy; Elimination; Filaria; Immunity; Vaccine; Wolbachia

Indexed keywords

ALBENDAZOLE; ANTIBIOTIC AGENT; ANTINEMATODAL AGENT; DIETHYLCARBAMAZINE; DOXYCYCLINE; VACCINE;

DRUG EFFECT; DRUG SAFETY; FILARIASIS; GENETIC PREDISPOSITION; HOST; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MEDICAL RESEARCH; NEMATODE; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; REVIEW; SIDE EFFECT; VECTOR CONTROL; WOLBACHIA ENDOSYMBIONT; WUCHERERIA BANCROFTI;

CLINICAL TRIALS; FILARIASIS; FILARICIDES; HUMANS; MOSQUITO CONTROL; ONCHOCERCIASIS; VACCINES;

EID: 0142107376     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200310000-00006     Document Type: Review

References (89)

1. WHO. Onchocerciasis and its control. WHO Tech Rep Ser 1995; 852:1-103.
2. WHO. Lymphatic filariasis. [WHO information fact sheets] 2000; http:// www.who.int/inf-fs/en/fact102.html. [Accessed April 1, 2003]
3. WHO. Onchocerciasis. [WHO information fact sheets] 2000; http:// www.who.int/inf-fs/en/fact095.html. [Accessed April 1, 2003]
4. Brattig NW, Lepping B, Timmann C, et al. Onchocerea volvulus-exposed persons fail to produce interferon-gamma in response to O. volvulus antigen but mount proliferate responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density. J Infect Dis 2002; 185:1148-1154. This was one of the largest studies on the cellular immune response to O. volvulus antigen with very sound statistics.
5. Henry NL, Law M, Nutman TB, Klion AD. Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure. J Infect Dis 2001; 183:512-516.
6. Doetze A, Satoguina J, Burchard G, et al. Antigen-specific cellular hyporesponsiveness in generalized Onchocerciasis is mediated by Th3/Tr1-type cytokines IL-10 and TGF-beta but not by a Th1 to Th2 shift. Int Immunol 2000; 12:623-630.
7. Steel C, Nutman TB. Ctla-4 in filarial infections: implications for a role in diminished T cell reactivity. J Immunol 2003; 170:1930-1938. This was the first study showing involvement of a regulatory cell marker CTLA-4 in a larger group of Onchocerciasis patients.
8. Satoguina J, Mempel M, Larbi J, et al. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect 2002; 4:1291-1300. The authors describe the characterisation of T regulatory cells cloned from onchocercomas.
9. Hoerauf A, Brattig N. Resistance and susceptibility in human onchocerctasis: beyond Th1 vs. Th2. Trends Parasitol 2002; 18:25-31.
10. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003; 3:189-198.
11. Gomez-Escobar N, Gregory WF, Maizels RM. Identification of tgh-2, a filarial nematode homolog of Caenorhabditis elegans daf-7 and human transforming growth factor beta, expressed in microfilarial and adult stages of Brugia malayi. Infect Immun 2000; 68:6402-6410.
12. Schonemeyer A, Lucius R, Sonnenburg B, et al. Modulation of human T cell responses and macrophage functions by onchocystatin, a secreted protein of the filarial nematode Onchocerea volvulus. J Immunol 2001; 167:3207-3215.
13. Zang X, Taylor P, Wang JM, et al. Homologues of human macrophage migration inhibitory factor from a parasitic nematode. Gene cloning, protein activity, and crystal structure. J Biol Chem 2002; 277:44261-44267. This, as well as articles by Schonemeyer et al. [12] and Whelan et al. [15], identify filaria-derived molecules which modify the immune system.
14. van der Kleij D, Latz E, Brouwers JF, et al. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem 2002; 277:48122-48129. These authors also identify filario-derived molecules which modify the immune system.
15. Whelan M, Harnett MM, Houston KM, et al. A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells. J Immunol 2000; 164:6453-6460.
16. Hoerauf A, Kruse S, Brattig NW, et al. The variant Arg110GIn of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect 2002; 4:37-42.
17. Abraham D, Lucius R, Trees AJ. Immunity to Onchocerca spp. in animal hosts. Trends Parasitol 2002; 18:164-171.
18. Hoffmann W, Petit G, Schulz-Key H, et al. Litomosoides sigmodontis in mice: reappraisal of an old model for filarial research. Parasitol Today 2000; 16:387-389.
19. Martin C, Saeftel M, Vuong PN, et al. B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. Infect Immun 2001; 69:7067-7073.
20. Korten S, Volkmann L, Saeftel M, et al. Expansion of NK cells with reduction of their inhibitory Ly-49A, Ly-49C, and Ly-49G2 receptor-expressing subsets in a murine helminth infection: contribution to parasite control. J Immunol 2002; 168:5199-5206.
21. Cook JA, Steel C, Ottesen EA. Towards a vaccine for onchocerciasis. Trends Parasitol 2001; 17:555-558.
22. Lustigman S, James ER, Tawe W, Abraham D. Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol 2002; 18:135-141. This is a comprehensive review on O. volvulus recombinant antigens that showed (or did not) protection in mouse models.
23. Williams SA, Laney SJ, Lizotte-Waniewski M, Bierwert LA. The River Blindness Genome Project. Trends Parasitol 2002; 18:86-90.
24. Brattig N, Büttner DW, Hoerauf A. Neutrophil accumulation around Onchocerca worms and chemotaxis of neutrophils are dependent on Wolbachia endobacteria. Microbes Infect 2001; 3:439-446
25. Brattig NW, Rathjens U, Ernst M, et al. Lipopolysaccharide-like molecules derived from Wolbachia endobacteria of the filaria Onchocerca volvulus are candidate mediators in the sequence of inflammatory and anti-inflammatory responses of human monocytes. Microbes Infect 2000; 2:1147-1157
26. Taylor MJ, Cross HF, Bilo K. Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J Exp Med 2000; 191:1429-1436.
27. Pfarr KM, Fischer K, Hoerauf A. Involvement of Toll-like receptor 4 in the embryogenesis of the rodent filaria Litomosoides sigmodontis. Med Microbiol Immunol 2003; 192:53-56. This study showed that Toll-like receptor 4 deficiency can lead to a higher degree of susceptibility to murine filariasis.
28. Andre Av A, Blackwell NM, Hall LR, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002; 295:1892-1895. This study clearly demonstrated that Wolbachia endosymbionts are essential for keratitis development in the mouse model.
29. Bazzocchi C, Ceciliani F, McCall JW, et al. Antigenic role of the endosymbionts of filarial nematodes: IgG response against the Wolbachia surface protein in cats infected with Dirofilaria immitis. Proc R Soc Lond B Biol Sci 2000; 267:2511-2516.
30. Punkosdy GA, Dennis VA, Lasater BL, et al. Detection of serum IgG antibodies specific for Wolbachia surface protein in rhesus monkeys infected with Brugia malayi. J Infect Dis 2001; 184:385-389.
31. Fischer P, Schmelz C, Bandi C, et al. Tunga penetrans: molecular identification of Wolbachia endobacteria and their recognition by antibodies against proteins of endobacteria from filarial parasites. Exp Parasitology (in press).
32. Dreyer G, Addiss D, Dreyer P, Noroes J. Basic lymphoedema management. Treatment and prevention of problems associated with lymphatic filariasis. Hollis: Hollis Publishing Company; 2002. This book presents excellent work on the practical aspects of lymphoedema prevention and treatment. The book was written by the team that discovered the impact of exogenous bacteria on the pathogenesis of lymphoedema and that has the most experience in its management.
33. Ottesen EA, Dowdle WR, Fenner F, et al. How is eradication to be defined and what are the biological criteria? In: Dowdle WR, Hopkins DR, editors. The eradication of infectious diseases. Chichester: John Wiley & Sons; 1998. pp. 47-59.
34. Dadzie Y, Neira M, Hopkins D. Final report of the conference on the eradicability of Onchocerciasis. Filaria J 2003; 2:2.
35. WHO. Lymphatic filariasis: progress report on the programme in 2002. Weekly Epidem Rep 2003; 78:171-179
36. Richards FO, Boatin B, Sauerbrey M, Seketeli A. Control of onchocerciasis today: status and challenges. Trends Parasitol 2001; 17:558-563.
37. Plaisier AP, Alley ES, van Oortmarssen GJ, et al. Required duration of combined annual ivermectin treatment and vector control in the Onchocerciasis Control Programme in West Africa. Bull Wld Hlth Org 1997; 75:237-245.
38. Abiose A, Homeida M, Liese B, et al. Onchocerciasis control strategies. Lancet 2000; 356:1523-1524
39. Winnen M, Plaisier AP, Alley ES, et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 2002; 80:384-391.
40. Borsboom GJ, Boatin BA, Nagelkerke NJ, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/ eradication in WestAfrica. Filavia J 2003; 2:9. This is a comprehensive meta-analysis of data collected during the time when the Onchocerciasis Control Programme in West Africa was active, showing clearly that annual mass administration of ivermectin will not lead to elimination of onchocerciasis from Africa. This is Likely to influence the refining of the goals regarding elimination of onchocerciasis at WHO.
41. Feng XP, Hayashi J, Beech RN, Prichard RK. Study of the nematode putative GABA type-A receptor subunits: evidence for modulation by ivermectin. J Neurochem 2002; 83:870-878.
42. Prichard R. Anthelmintic resistance. Vet Parasitol 1994; 54:259-268.
43. Boussinesq M, Gardon J, Kamgno J, et al. Relationships between the prevalence and intensity of Loa loa infection in the Central Province of Cameroon. Ann Trop Med Parasitol 2001; 95:495-507.
44. Takougang I, Meremikwu M, Wandji S, et al. Rapid assessment method for prevalence and intensity of Loa loa infection. Bull World Health Organ 2002; 80:852-858.
45. Ottesen EA. The global programme to eliminate lymphatic filariasis. Trop Med Int Hlth 2000; 5:591-594.
46. Molyneux DH, Taylor MJ. Current status and future prospects of the Global Lymphatic Filariasis Programme. Curr Opin Infect Dis 2001; 14:155-159
47. Horton J, Witt C, Ottesen EA, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000; 121 (Suppl):S147-S160.
48. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 2000; 121 (Suppl):S113-S132.
49. Pani S, Subramanyam Reddy G, Das L, et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital-based study. Filaria J 2002; 1:1.
50. Dunyo SK, Nkrumah FK, Simonsen PE. A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Trans R Soc Trop Med Hyg 2000; 94:205-211.
51. Ottesen EA. Major progress toward eliminating lymphatic filariasis. N Engl J Med 2002; 347:1885-1886.
52. Ramzy RM, el-Setouhy M, Helmy H, et al. The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt. Am J Trop Med Hyg 2002; 67:196-200. This is an important original report on the effect of DEC single-dose mass treatment in a low endemicity setting.
53. Farid HA, Hammad RE, Soliman DA, et al. Relationships between Wuchereria bancrofti microfilaria counts in human blood and parasite uptake and maturation in Culex pipiens, with observations on the effects of diethylcarbamazine treatment on these parameters. Am J Trop Med Hyg 2003; 68:286-293.
54. Esterre P, Plichart C, Sechan Y, Nguyen NL. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop Med Int Health 2001; 6:190-195.
55. Bockarie MJ, Tisch DJ, Kastens W, et al. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 2002; 347:1841-1848. This is a very thorough analysis of the impact of DEC mass treatment in high and medium endemicity areas. The study also shows an impact of DEC mass treatment on disease symptoms such as hydrocele and lymphedema.
56. Hoerauf A, Adjei O, Büttner DW. Antibiotics for the treatment of onchocerciasis and other filarial infections. Curr Opin Invest Drugs 2002; 3:533-537.
57. McGarry H, Pfarr K, Egerton G, et al. Evidence against Wolbachia symbiosis in Loa loa. Filaria J 2003; 2:10. This study, and [58•], clarified the absence of Wolbachia from Loa loa and addressed the implications for assessment of Loa-associated pathology.
58. Buttner DW, Wanji S, Bazzocchi C, et al. Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa. Filaria J 2003; 2-10. See Ref [57•].
59. Taylor MJ, Hoerauf A. A new approach to the treatment of filariasis. Curr Opin Infect Dis 2001; 14:727-731.
60. Langworthy S, Renz A, Mackenstedt U, et al. Macrofilaricidal activity of tetracycline against the filarial nematode, Onchocerca ochengi: elimination of Wolbachia preceeds worm death and suggests a dependent relationship. Proc Royal Soc London Ser B 2000; 267:1063-1069
61. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355:1242-1243
62. Hoerauf A, Mand S, Adjei O, et al. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001; 357:1415-1416
63. Hoerauf A, Mand S, Volkmann L, et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 2003; 5:261-273. This formed an extensive study on the effects of Wolbachia depletion from O. volvulus by doxycycline, showing comprehensively that Wolbachia depletion precedes loss of female worm fertility.
64. Hoerauf A, Walter RD, Remme H, et al. Call to consolidate achievements for onchocerciasis and lymphatic filariasis control. Trends Parasitol 2001; 17:566-567.
65. Hoerauf A, Büttner DW, Adjei O, Pearlman E. Clinical Review: Onchocerciasis. Endosymbiotic Wolbachia bacteria in the worms are targets for a new therapeutic approach. BMJ 2003; 326:207-210.
66. Hoerauf A, Mand S, Fischer K, et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol 2003; 192:5. This paper is the first to show the effect of doxycycline on bancroftian filariasis.
67. Cross HF, Haarbrink M, Egerton G, et al. Severe reactions to filarial chemotherapy are associated with the release of Wolbachia endosymbionts into the blood. Lancet 2001; 358:1873-1875.
68. Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002; 185:805-811. This study, as well as that by Cross [66], clearly shows the association of Wolbachia with adverse reactions to microfilaricidal treatment.
69. TIGR. What's New: The TIGR Brugia malayi Genome Project [online newsletter] 2002; http://www.tigr.org/tdb/e2k1/bma1/new.shtml. [Accessed April 1, 2003.]
70. Williams SA. The River Blindness Genome Project (RBGP). 2002; http:// www.math.smith.edu/~sawlab/OnchoNet/RBGP.html.
71. Ware J, Moran L, Foster J, et al. Sequencing and analysis of a 63 kb bacterial artificial chromosome insert from the Wolbachia endosymbiont of the human filarial parasite Brugia malayi. Int J Parasitol 2002; 32:159-166.
72. Nutman TB. Future directions for vaccine-related onchocerciasis research. Trends Parasitol 2002; 18:237-239.
73. Chaussabel D, Tolouei Semnani R, McDowell MA, et al. Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood 2003; 27:27. This was an important study marking the entry of filariasis research into microarray technology.
74. Loke P, Nair MG, Parkinson J, et al. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol 2002; 3:7. This was another important study marking the entry of filariasis research into microarray technology.
75. Williams SA, Laney SJ, Bierwert LA, et al. Development and standardization of a rapid, PCR-based method for the detection of Wuchereria bancrofti in mosquitoes, for xenomonitoring the human prevalence of bancroftian filariasis. Ann Trop Med Parasitol 2002; 96 (Suppl 2):S41-S46. This work was borne out of the need to standardize the polymerase chain reaction-based surveillance of W. bancrofti transmitting vectors. It is important for control aspects.
76. Guevara AG, Vieira JC, Lilley BG, et al. Entomological evaluation by pool screen polymerase chain reaction of Onchocerca volvulus transmission in Ecuador following mass Mectizan distribution. Am J Trop Med Hyg 2003; 68:222-227.
77. Fischer P, Wibowo H, Pischke S, et al. PCR-based detection and identification of the filarial parasite Brugia timori from Alor Island, Indonesia. Ann Trop Med Parasitol 2002; 96:809-821.
78. Fischer P, Boakye D, Hamburger J. Polymerase chain reaction-based detection of lymphatic filariasis. Med Microbiol Immunol (Berl) 2003; 192:3-7.
79. Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001; 6:582-606.
80. Toe L, Adjami AG, Boatin BA, et al. Topical application of diethylcarbamazine to detect onchocerciasis recrudescence in west Africa. Trans R Soc Trop Med Hyg 2000; 94:519-525.
81. Boatin BA, Toe L, Alley ES, et al. Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. Parasitology 2002; 125:545-552.
82. Gyapong JO, Kyelem D, Kleinschmidt I, et al. The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countries. Ann Trop Med Parasitol 2002; 96:695-705. This work picks up an important but nevertheless neglected aspect: the 'patchy' distribution of lymphatic filariasis in Africa and the consequences for mass treatment.
83. Dreyer G, Noroes J, Figueredo-Silva J. New insights into the natural history and pathology of bancroftian filariasis: implications for clinical management and filariasis control programmes. Trans R Soc Trop Med Hyg 2000; 94:594-596.
84. Dreyer G, Figueredo-Silva J, Carvalho K, et al. Lymphatic filariasis in children: adenopathy and its evolution in two young girls. Am J Trop Med Hyg 2001; 65:204-207.
85. Dreyer G, Addiss D, Roberts J, Noroes J. Progression of lymphatic vessel dilatation in the presence of living adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 2002; 96:157-161.
86. Mand S, Marfo-Debrekyei Y, Dittrich M, et al. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2003; 2:3. This study makes use of the possibility to publish video images in a web-based journal, thus allowing a better grasp of the technique of ultrasonography to detect living motile worms in bancroftian filariasis.
87. Maizels RM, Kurniawan-Atmadja A. Variation and polymorphism in helminth parasites. Parasitology 2002; 125 (Suppl):S25-S37.
88. Duke BO. A plea to continue the search for an Onchocerca volvulus macrofilaricide. Trans R Soc Trop Med Hyg 2002; 96:575-576.
89. Shu L, Katholi CR, Higazi T, Unnasch TR. Analysis of the Brugia malayi HSP70 promoter using a homologous transient transfection system. Mol Biochem Parasitol 2003; 128:67-75.